Scientific Leadership

Dr. Karsdal joined Nordic Bioscience in 2001 and rose to CEO in 2010. Dr. Karsdal has led the development of FDA-approved and supported molecular diagnostics and more than 100 commercialized biomarker assays, including both ELISA assays and assays available on high precision automated platforms.

He has extensive experience with clinical trial design in combination with clinical use of biochemical markers. He has conducted extensive research in the field of fibrosis, rheumatology (rheumatoid arthritis and osteoarthritis), diabetes and more. Dr. Karsdal has published more than 700 peer-reviewed articles and has presented at numerous international scientific conferences. Dr. Karsdal oversees several major partnerships as well as over 150 collaborators in Copenhagen.

H-index: 101. i10-index: 607. Citations: 40.508, as of June 2025.

Dr. Manon-Jensen has been with Nordic Bioscience for more than 8 years, where she was the principal investigator of hemophilia research, discovering novel biomarkers and utilizing her knowledge in the clinical needs for biomarker usage in clinical trials. Today, as the Head of Clinical Laboratory, she is responsible for the daily operations and business of our CAP-certified and CLIA-compliant laboratory.

Her responsibilities include overseeing the measurements we deliver to our customers, biobank, project and data management, LIMS, and custom/CLSI validations. Dr. Manon-Jensen spearheads the only CAP laboratory in Scandinavia and works to differentiate our services from protein array service providers. With her leadership, our lab subscribes to the highest quality standards, and among other things, we are partnering with Roche and advancing IDS i10 platform investments.

H-index: 24. i10-index: 48. Citations: 3.392, as of June 2025.

Dr. Genovese joined Nordic Bioscience in 2011 and since 2014 has led a group focused on the application of markers for ECM remodeling in renal and cardiovascular disease. Her group’s activities range from biomarker discovery and development to clinical and preclinical validation of biomarkers in various chronic kidney diseases (CKD, DKD, IgAN, ADPKD, kidney transplantation) and cardiovascular diseases (HFpEF, atherosclerosis, myocardial infarction, atrial fibrillation).

H-index: 30. i10-index: 42. Citations: 3.663, as of June 2025.

Dr. Willumsen joined Nordic Bioscience in 2012 and assumed the position of department head in oncology in 2016. His research group focuses on the development of blood-based biomarkers to quantify tumor matrix in serum of cancer patients to understand pharmacodynamics/efficacy/resistance mechanisms of treatments. The group’s research activities range from biomarker discovery to preclinical and clinical validation of results. In 2022, Dr. Willumsen was appointed as Director of Oncology.

H-index: 30. i10-index: 59. Citations: 2.824, as of June 2025.

Dr. Holm Nielsen has been with Nordic Bioscience since 2015, where she started as a PhD Fellow and since then has been appointed Scientific Director, focusing on Dermatology. Her dedicated Dermatology team focuses on the development and evaluation of translational blood-based biomarkers to support precision medicine and drug development.

Her favorite collagens are type VI and VII, due to their role in fibrotic and inflammatory skin diseases, such as Hidradenitis Suppurativa, Scleroderma, Atopic Dermatitis, and rare blistering diseases. She is a member of the European Academy of Dermatology & Venerology (EADV), American Society for Matrix Biology (ASMB), and International Society for Matrix Biology (ISMB), where she enjoys discussing scientific stories and sharing her experiences of working in both academia and the biotechnology and pharmaceuticals industry.

H-index: 24. i10-index: 42. Citations: 2.220, as of June 2025.

Kishwar joined Nordic Bioscience in 2011 after graduating from the Technical University of Denmark. Since 2013 she has been heading the biomarker laboratory associated with the patented tests developed by Nordic Bioscience. Today she leads a team of more than 30 technicians and dedicated project managers providing high quality laboratory services covering all aspects of testing programs for our key customers in the biotech and pharmaceutical industry.